Ianalumab(Ianalumab) - 药物靶点：BAFF-R_在研适应症：系统性红斑狼疮，免疫性血小板减少症，温热型自身免疫性溶血性贫血_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

NOV-5、VAY-736、VAY736

靶点

BAFF-R

作用方式

抑制剂

作用机制

BAFF-R抑制剂(B细胞活化因子受体抑制剂)

治疗领域

免疫系统疾病眼部疾病血液及淋巴系统疾病+ [7]

在研适应症

系统性红斑狼疮免疫性血小板减少症温热型自身免疫性溶血性贫血+ [11]

非在研适应症

难治性慢性淋巴细胞白血病特发性肺纤维化边缘区B细胞淋巴瘤+ [3]

原研机构

MorphoSys AG

在研机构

Novartis Pharma AGLonza AG

Novartis Pharmaceuticals Corp.

+ [6]

非在研机构-

权益机构

Novartis AG

MorphoSys AG

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 155090L

来源: *****

Sequence Code 155096H

来源: *****

关联

33

项与 Ianalumab 相关的临床试验

NCT07039422

/ Not yet recruiting临床2期

Exploratory Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (VAY RE-HIT)

This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).

开始日期2025-08-01

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06711887

/ Recruiting临床3期

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

The purpose of this 2-year extension study is the evaluation of the efficacy and safety
1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.

开始日期2025-05-19

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06411639

/ Withdrawn临床1期

A Multicenter, Open-label, Single-arm, Multiple-dose Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adult Participants With Autoimmune Diseases

The purpose of this pharmacokinetic (PK) study is to describe the PK profile of ianalumab following s.c. administration in Chinese participants with systemic lupus erythematosus (SLE) and/or Sjögren's disease (SjD). Collection of intensive PK data from Chinese population had been designed in the ianalumab Phase 3 studies of SjD CVAY736A2302 (NCT05349214) and lupus nephritis (LN) CVAY736K12301 (NCT05126277) on an optional basis. This study is conducted to provide supplementary Chinese PK data in addition to the intensive PK data from the two Phase 3 studies .

开始日期2024-11-25

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

100 项与 Ianalumab 相关的临床结果

登录后查看更多信息

100 项与 Ianalumab 相关的转化医学

登录后查看更多信息

100 项与 Ianalumab 相关的专利（医药）

登录后查看更多信息

20

项与 Ianalumab 相关的文献（医药）

2025-05-01·Arthritis & Rheumatology

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study

Article

作者: Hueber, Wolfgang ; Fox, Robert ; Schulze‐Koops, Hendrik ; Junge, Guido ; Papas, Athena ; Luo, Wen‐Lin ; Bowman, Simon J. ; Grader‐Beck, Thomas ; Fisher, Benjamin A. ; Woznicki, Janice ; Moots, Robert J. ; De Vita, Salvatore ; Sopala, Monika ; Mariette, Xavier ; Barcelos, Filipe ; Avrameas, Alexandre ; Dörner, Thomas

Objective:

The objective of this study was to report 52‐week safety and efficacy of ianalumab from phase 2b dose‐finding study in patients with Sjögren's disease (SjD).

Methods:

Patients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks until week 24 (treatment period [TP]1). At week 24, patients on 300 mg were rerandomized to continue 300 mg or receive placebo until week 52 (TP2), patients on placebo were switched to ianalumab 150 mg, and patients on 5 and 50 mg directly entered posttreatment safety follow‐up. Patients who discontinued treatment early or completed treatment entered safety follow‐up (≥20 weeks).

Results:

During TP1, 190 patients were randomized (placebo = 49, 5 mg = 47, 50 mg = 47, 300 mg = 47). Of these 190 patients, 90 (47.4 %; 43 continued 300 mg and 47 received placebo) entered TP2, and 81 of 90 (90.0%) completed the study treatment. By week 52, efficacy was sustained in patients who continued 300 mg in TP2 (EULAR Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index, patient global assessment, and physician global assessment change from week 24: −1.45, −0.46, −4.69, and −6.86, respectively). Stimulated salivary flow rates and autoantibody levels numerically improved in the 300 mg group. Treatment‐emergent adverse events were not dose‐dependent, except for injection‐site reactions. Cases of decreased neutrophil counts (Common Terminology Criteria for Adverse Events v4.03 grade 3 according to laboratory listings) were observed in three patients during the posttreatment follow‐up, occurring at 3.5, 5.5, and 3 months, after the last ianalumab administration. None were associated with infection except one incidental finding of asymptomatic cytomegalovirus infection (IgM‐positive).

Conclusion:

In patients with SjD, ianalumab 300 mg demonstrated sustained efficacy through week 52 and a favorable safety profile up to two years of follow‐up.

2024-09-01·Expert Review of Hematology

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

Review

作者: Arnold, Donald M. ; Harnett, Brian ; Al‐Samkari, Hanny ; Dalmia, Shreyash ; Al-Samkari, Hanny ; Arnold, Donald

INTRODUCTION:

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelets and an increased risk of bleeding. Platelet autoantibodies target major platelet glycoproteins and cause Fc-mediated platelet destruction in the spleen and reticuloendothelial systems. As mechanisms of disease, platelet autoantibodies are important therapeutic targets. Neonatal Fc receptor (FcRn) antagonists are a new class of therapeutics that reduce the half-life of immunoglobulin G including pathogenic platelet autoantibodies. Spleen tyrosine kinase (Syk) inhibitors interfere with Fc-mediated platelet clearance. Bruton's tyrosine kinase (BTK) inhibitors and B-cell activating factor (BAFF) inhibitors reduce antibody production. The efficacy of these targeted therapies provides new support for the role of platelet autoantibodies in pathogenesis of ITP even these antibodies can be difficult to detect.

AREAS COVERED:

This review includes an in-depth exploration of the pathophysiologic mechanisms of ITP, focusing on autoantibodies. Treatments outlined in this review include a) FcRn antagonists, b) complement inhibitors, c) B-cell directed therapies such as BTK inhibitors, and anti-BAFF agents, d) Syk inhibitors, e) plasma-cell directed therapies, and f) novel cellular therapeutic products.

EXPERT OPINION:

Platelet autoantibodies are often elusive in ITP, yet novel treatments targeting this pathway reinforce their role in the pathogenesis of this autoimmune platelet disorder.

2024-06-01·DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Review

作者: Witte, Torsten ; Ernst, Diana ; Zehrfeld, Nadine

86

项与 Ianalumab 相关的新闻（医药）

23 小时之前

·Firstwordpharma

RemeGen’s dual-target fusion protein triumphs in late-stage Sjögren's study

RemeGen on Wednesday said its dual-target fusion protein telitacicept crossed the finish line in a late-stage study in primary Sjögren's syndrome, with the company aiming to submit a regulatory filing "promptly" with China’s National Medical Products Administration (NMPA).The Phase III trial randomised 381 Chinese patients with active primary Sjögren’s syndrome to receive weekly subcutaneous telitacicept at doses of 80 mg or 160 mg, or placebo, for 48 weeks. The primary endpoint measured the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at 24 weeks.Top-line results showed that telitacicept met the study’s main goal, demonstrating significant and sustained symptom improvement compared with placebo, alongside a favourable safety profile. Detailed findings will be presented at forthcoming medical conferences.Telitacicept — designed to selectively inhibit the two cytokines BlyS (also known as BAFF) and APRIL — holds approvals in China under the brand name Tai'ai to treat systemic lupus erythematosus (SLE), rheumatoid arthritis and generalised myasthenia gravis (gMG). In a late-stage gMG study in China reported earlier this year, telitacicept achieved a 4.8-point improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale over placebo at 24 weeks, meeting the trial’s primary endpoint. Additionally, it is being explored in IgA nephropathy.In June, cash-strapped Vor Bio secured ex-China rights to telitacicept in a deal potentially worth over $4 billion. A global late-stage trial of the drug in a broader gMG population is also under way, with preliminary results anticipated in the first half of 2027.Meanwhile, this week also saw yet another favourable Sjögren's readout, with Novartis' monoclonal antibody ianalumab (VAY736) succeeding in two pivotal studies.

临床结果临床3期上市批准

2025-08-13

·医药笔记

诺华：BAFF-R抗体干燥综合征、ITP三期临床接连成功

▎Armstrong 2025年8月11日，诺华宣布BAFF-R抗体Ianalumab治疗干燥综合征的量项三期临床NEPTUNUS-1、NEPTUNUS-2均达到主要终点，疾病活动度显著改善。Ianalumab有望成为首款干燥综合征新药。 2025年8月12日，诺华公布Ianalumab用于经激素治疗失败原发免疫性血小板减少症（ITP）的三期临床VAYHIT2顶线数据，关键次要终点治疗6个月时血小板计数显著改善。诺华预计将在2027年与一线治疗VAHIT1的结果一起递交上市申请。 Ianalumab最初由Morphosys（2024年被诺华29亿美元收购）研发，Morphosys为抗体工程的先驱，有多款合作开发的抗体药物管线，包括诺华合作的BAFF-R抗体Ianalumab、Anthos合作的FXI抗体Abelacimab、Ultragenyx合作的硬骨素抗体Setrusumab、礼来合作的ACVR2B抗体Bimagrumab、HiBio及天境生物合作的CD38抗体Delzartamab等。 BAFF-R在成熟B细胞的存活中发挥着关键作用，为BAFF的主要受体之一，TACI则同时为BAFF、APRIL的受体。TACI靶点泰它西普已经成药，Atacicept、Povetacicept则在仅仅追赶。诺华Ianalumab则引领了BAFF-R的临床探索，直到如今在干燥综合征、ITP完成POC。总结除了干燥综合征、ITP，诺华围绕Ianalumab还在探索狼疮性肾炎、系统性红斑狼疮、化脓性汗腺炎、全身性硬皮病等多项自免适应症。诺华在自免领域积累深厚，引领了IL-17A抗体、BTK抑制剂、BAFF-R抗体、CAR-T等多个赛道的进展。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期免疫疗法细胞疗法抗体药物偶联物并购

2025-08-12

·药明康德

13亿美元！拜耳囊获KRAS小分子抑制剂；首次！Keytruda联合疗法达3期试验主要与所有关键次要终点……

13亿美元！拜耳囊获KRAS小分子抑制剂拜耳（Bayer）与Kumquat Biosciences今日宣布，双方已就Kumquat公司KRAS G12D小分子抑制剂的全球独家许可及合作开发与商业化达成协议。根据协议，Kumquat将负责该药物1a期临床试验的启动与完成，而拜耳将接手后续的开发及商业化工作。Kumquat于2025年7月获得美国FDA许可开展该药物的临床试验。根据协议，Kumquat将获得最高达13亿美元的款项，包括预付款、临床与商业化里程碑付款等。此次合作聚焦于KRAS G12D抑制剂的研发，将补充拜耳在胰腺癌、结直肠癌及肺癌等精准肿瘤学领域的研发管线。KRAS突变存在于近四分之一的人类癌症中，其中KRAS G12D是最常见且致癌性最强的突变类型之一，但至今仍缺乏有效治疗手段。本次合作的达成，有望加速针对这一高未满足医疗需求的创新疗法研发进程。首次！Keytruda联合疗法达3期试验主要与所有关键次要终点默沙东（MSD）今日宣布，其3期临床试验KEYNOTE-905（EV-303）在患有肌层浸润性膀胱癌（MIBC）且不适合使用以顺铂为基础化疗的患者中取得积极的主要结果。研究显示，在手术（根治性膀胱切除术）前后联合使用PD-1抑制剂Keytruda（pembrolizumab）与抗体偶联药物Padcev（enfortumab vedotin），与单纯手术相比，在主要终点无事件生存期（EFS），以及关键次要终点总生存期（OS）和完全病理学缓解率（pCR）方面均取得了具有统计学意义和临床意义的改善。安全性方面，联合疗法的耐受性与各药物已知的安全性特征一致，未发现新的安全性信号。根据新闻稿，这是在不适合使用顺铂化疗的MIBC患者中，手术前后联合用药能够改善生存结局的首个系统性治疗方案，这也是该患者群体中首次取得积极结果的3期临床研究，标志着MIBC治疗领域的重要进展。 Keytruda是一种PD-1单克隆抗体，可阻断PD-1与其配体PD-L1和PD-L2之间的相互作用，从而激活T淋巴细胞，以发挥抗肿瘤功效。Padcev是一种抗体偶联药物，其靶点为nectin-4，这是一种位于细胞表面并在膀胱癌中高表达的蛋白质。临床前数据表明，这种药物的抗癌活性是由于它与表达nectin-4的细胞结合，然后将抗肿瘤药物MMAE内化并释放到细胞中，导致细胞不再增殖并出现程序性细胞死亡。每月一次！诺华抗体联合疗法3期试验结果积极诺华（Novartis）今日宣布，其在3期临床试验VAYHIT2中取得积极的主要结果。该研究评估了抗体ianalumab联合口服血小板生成素受体激动剂Promacta（eltrombopag）用于既往接受糖皮质激素治疗的原发性免疫性血小板减少症（ITP）患者的疗效。与安慰剂联合eltrombopag相比，ianalumab联合eltrombopag显著延长了至治疗失败的时间（TTF），这一主要终点衡量患者在治疗期间及之后维持安全血小板水平的时间长短。此外，在次要关键终点方面，接受联合治疗的患者在六个月时血小板计数持续改善的比例显著高于对照组。安全性分析显示，ianalumab的安全性特征与既往临床研究一致，未发现新的安全性信号。 Ianalumab是一款阻断BAFF受体的抗体疗法，在阻断BAFF信号传导的同时，可通过增强的抗体依赖性细胞毒性（ADCC）清除B细胞，有潜力带来更持久的疾病缓解。Ianalumab在ITP治疗中以每月一次、连续四次给药的方案，有望通过短程治疗实现长期疾病控制。目前，该药还在针对B细胞驱动的其他自身免疫性疾病中开展研究，包括正在进行的一线ITP及复发/难治性温抗体型自身免疫性溶血性贫血3期临床试验。参考资料： [1] Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure. Retrieved https://www.novartis.com/news/media-releases/novartis-ianalumab-phase-iii-trial-meets-primary-endpoint-itp-demonstrating-statistically-significant-improvement-time-treatment-failure [2] KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery. Retrieved August 12, 2025 from https://www.businesswire.com/news/home/20250811757766/en/KEYTRUDA-pembrolizumab-plus-Padcev-enfortumab-vedotin-ejfv-Significantly-Improved-Event-Free-and-Overall-Survival-and-Pathologic-Complete-Response-Rate-for-Certain-Patients-with-Muscle-Invasive-Bladder-Cancer-When-Given-Before-and-After-Surgery [3] Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology. Retrieved August 12, 2025 from https://businesswire.com/news/home/20250812240388/en/Bayer-and-Kumquat-Biosciences-Enter-Global-Exclusive-License-and-Collaboration-in-Precision-Oncology 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期引进/卖出抗体药物偶联物临床结果

100 项与 Ianalumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Ianalumab	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性红斑狼疮	临床3期	日本	诺华（中国）生物医学研究有限公司	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharma AG	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharma Stein AG	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharmaceuticals Corp.	2023-03-02
系统性红斑狼疮	临床3期	巴西	诺华（中国）生物医学研究有限公司	2023-03-02
系统性红斑狼疮	临床3期	巴西	Novartis Pharma Stein AG	2023-03-02
系统性红斑狼疮	临床3期	保加利亚	Novartis Pharmaceuticals Corp.	2023-03-02
系统性红斑狼疮	临床3期	加拿大	诺华（中国）生物医学研究有限公司	2023-03-02
系统性红斑狼疮	临床3期	加拿大	Novartis Pharma Stein AG	2023-03-02
系统性红斑狼疮	临床3期	加拿大	Novartis Pharma AG	2023-03-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05885555 (VAYHIT3, EHA2025)	临床2期	免疫性血小板减少症	41	Ianalumab 9 mg/kg	膚襯艱遞鬱鏇鏇顧鑰製(憲膚夢獵窪選廠觸餘廠) = 82% of pts experienced at least one adverse event 網願範齋構製構範繭糧 (範遞顧築築願夢構窪願 ) 更多	积极	2025-05-14
NCT05885555 (PS2237, EHA2025)	临床2期	免疫性血小板减少症	10	Ianalumab	簾積醖衊製醖鑰艱憲蓋(願獵淵網壓積淵鑰鏇淵) = 構鏇襯窪顧襯製襯遞艱獵顧製遞顧範襯網憲鑰 (夢憲衊鹹壓淵鏇糧夢鑰 ) 更多	积极	2025-05-14
NCT05885555 (ASH2024)	临床2期	免疫性血小板减少症	-	Ianalumab 9 mg/kg	壓衊簾餘網範蓋繭窪範(醖築壓鑰艱顧鬱鑰鏇網) = all 10 patients (100%) and 3 patients (30%) experienced any-grade adverse events (AEs) and Grade ≥3 AEs, respectively. Six patients had infections and 2 patients had infusion-related reactions; all of these events were Grade 1 or 2. No patients discontinued treatment due to AEs. After Week 25 there was one death due to pulmonary edema, which was assessed as unrelated to ianalumab. No safety signal was detected up to data cutoff. 顧淵襯繭範淵鏇夢範築 (鬱築鹽網壓壓鏇鹽艱獵 ) 更多	-	2024-12-09
NCT03656562 (CVAY736X2208, EULAR 12024 \| EULAR 22024) 人工标引	临床2期	系统性红斑狼疮	67	ianalumab 300 mg subcutaneous	餘積鹽鏇餘顧憲壓衊窪(願簾鏇憲壓襯築艱糧製) = 淵鏇鏇壓淵齋蓋壓簾壓衊鏇衊網願糧蓋網壓選 (簾鹽鬱齋窪鑰繭範壓襯 )	积极	2024-06-14
				placebo	餘積鹽鏇餘顧憲壓衊窪(願簾鏇憲壓襯築艱糧製) = 積艱醖膚獵簾鑰獵鹽鬱衊鏇衊網願糧蓋網壓選 (簾鹽鬱齋窪鑰繭範壓襯 )
EULAR2023	N/A	系统性红斑狼疮	67	Ianalumab	獵夢鏇觸遞醖膚糧觸簾(選糧壓壓膚襯構醖遞蓋) = 2 AE-related dropouts occurring during open-label treatment, one in ianalumab arm (morphoea) and one with placebo (worsening of SLE) 鹹鹹餘廠鹹製繭繭繭築 (鑰艱選壓淵觸蓋構製鹽 ) 更多	-	2023-05-31
				Placebo
NCT03400176 (AACR2023) 人工标引	临床1期	慢性淋巴细胞白血病	39	VAY736+ibrutinib	淵鏇糧鑰鑰築鑰壓鹽壓(鏇壓觸選餘鹽簾夢選鑰) = 齋壓蓋顧醖簾醖艱遞構淵糧觸鹹構顧醖膚壓夢 (範壓齋築獵鏇糧鹽鬱選 ) 更多	积极	2023-04-15
				VAY736+ibrutinib (1L)	淵鏇糧鑰鑰築鑰壓鹽壓(鏇壓觸選餘鹽簾夢選鑰) = 範襯積獵願齋夢遞糧獵淵糧觸鹹構顧醖膚壓夢 (範壓齋築獵鏇糧鹽鬱選 ) 更多
NCT03400176 (ASH 12021 \| ASH 22021) 人工标引	临床1期	慢性淋巴细胞白血病一线 \| 二线	32	Ibrutinib+Ianalumab	襯獵遞鹽網膚築顧鏇窪(襯願網鏇糧醖顧遞窪襯) = 壓範願淵觸鏇醖壓鬱鏇壓鑰選夢襯繭構構選獵 (憲遞糧鑰衊艱選醖選憲 ) 更多	积极	2021-11-05
NCT01930175 (CTgov)	临床2期	天疱疮	13	VAY736 (VAY736 3 mg/kg)	衊範餘襯鏇壓願衊衊憲(醖積鏇選餘淵廠繭廠積) = 築鏇齋繭醖襯鹹顧繭選築鏇願範艱壓艱醖構膚 (壓鹹夢觸顧夢鏇鑰積廠, 1.836) 更多	-	2020-10-19
				VAY736 (VAY736 10 mg/kg)	衊範餘襯鏇壓願衊衊憲(醖積鏇選餘淵廠繭廠積) = 願選積糧壓範夢壓壓顧築鏇願範艱壓艱醖構膚 (壓鹹夢觸顧夢鏇鑰積廠, 8.273) 更多
EULAR2020	临床2期	原发性干燥综合征 anti-Ro/SSA+	190	VAY736 300mg	構艱選製網齋淵顧醖醖(糧蓋獵襯選窪淵繭糧蓋) = 範鹽鹽觸窪醖糧醖鏇醖鹽膚夢願廠壓齋糧鑰壓 (鬱顧餘遞膚鹹築鹹壓淵 )	积极	2020-06-03
				Placebo	構艱選製網齋淵顧醖醖(糧蓋獵襯選窪淵繭糧蓋) = 鹽鬱範簾憲醖襯範鬱壓鹽膚夢願廠壓齋糧鑰壓 (鬱顧餘遞膚鹹築鹹壓淵 )
NCT02038049 (CTgov)	临床2期	复发-缓解型多发性硬化	8	VAY736 (VAY736)	選壓餘鑰襯範襯鹽獵觸 = 顧蓋壓襯糧範膚鏇齋鹹鑰衊選願網窪製繭築鹹 (壓襯蓋衊製鬱淵鏇餘壓, 顧築網築鹽壓憲淵鬱憲 ~ 觸襯構窪顧蓋衊憲醖觸) 更多	-	2019-10-30
				Placebo (Placebo to VAY736)	選壓餘鑰襯範襯鹽獵觸 = 鏇壓糧網夢構夢蓋製醖鑰衊選願網窪製繭築鹹 (壓襯蓋衊製鬱淵鏇餘壓, 齋簾顧壓觸鏇糧顧衊範 ~ 願網鹹夢顧艱鏇願積繭) 更多